Genmab A (GMAB) Shares Outstanding (Weighted Average) (2018 - 2026)

Genmab A has reported Shares Outstanding (Weighted Average) for 7 years, with the latest figure at $1.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 12399999900.0% year-over-year to $1.9 billion; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (up 12399999900.0% YoY), and the FY2025 full-year result was $10.0 million, changed 0.0% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $1.9 billion, up from $10.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $1.9 billion in Q1 2026, with the low at $6.09 in Q2 2024.
• Historically, Shares Outstanding (Weighted Average) has averaged $576.9 million across 4 years, with a median of $10.0 million in 2023.
• The largest YoY upside for Shares Outstanding (Weighted Average) was 31264367716.09% in 2025 against a maximum downside of 12.63% in 2025.
• Genmab A's Shares Outstanding (Weighted Average) stood at $10.0 million in 2023, then changed by 0.0% to $10.0 million in 2024, then changed by 0.0% to $10.0 million in 2025, then soared by 19120.0% to $1.9 billion in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $1.9 billion (Q1 2026), $10.0 million (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.